Prostate cancer has high incidence worldwide and the development of novel therapies are urgently needed. Currently used androgen receptor signaling inhibitors (ARSI) targeting the full-length androgen receptor (ARFL) are initially effective, however most patients develop therapy resistance denominated as castration-resistant prostate cancer (CRPC). On the molecular level, the constitutively active AR splice variant ARV7 promotes CRPC progression and cannot be targeted by ARSI due to an absent ligand binding domain. However, due to its distinct 3' untranslated region (3′UTR) compared to ARFL, ARV7 may be differentially regulated by microRNAs (miRNAs), which could be used as therapeutic opportunity. Of note, single nucleotide polymorphisms (SNPs) within this region could influence miRNA binding. Using an in silico screening approach, we identified SNPs predicted to alter miRNA binding sites in the ARV7 3′UTR. Selected miRNAs were functionally evaluated in CRPC cells for their effects on ARV7 and ARFL expression, allele-specific binding, and cell proliferation. Among the candidates with predicted allele-specific ARV7 binding, hsa-miR-574-5p was selected for further analyses after confirmation of allele-specific effects in luciferase assays. Overexpression of hsa-miR-574-5p in the ARV7-expressing cell line 22Rv1 was able to reduce ARV7 mRNA and protein levels without affecting ARFL. Functionality of this miRNA was demonstrated by reduced proliferation of 22Rv1 upon induced expression of hsa-miR-574-5p. In conclusion, we identified hsa-miR-574-5p as a miRNA binding to the 3'UTR of ARV7. This finding may be useful for the development of therapies specifically targeting ARV7 driving CRPC.